Skip to main content

Table 1 Clinical and demographic features of the diagnostic cohorts

From: Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer’s disease

 

Con

aMCI

AD

VaD

PDD

Serum

     

 No.

102

91

164

43

30

 Sex, female/male

57/45

51/40

87/77

13/30**

15/15

 Age, years (SD)

65.45 ± 7.88

66.66 ± 7.09

67.20 ± 8.63

68.42 ± 8.94

64.37 ± 8.43

 Education level, years (SD)

NA

12.94 ± 3.58

11.11 ± 3.83

10.95 ± 4.66

11.17 ± 3.43

 MMSE score, mean (SD)

NA

27.96 ± 1.04

17.14 ± 6.34

20.42 ± 5.04

23.20 ± 2.76

 MOCA score, mean (SD)

NA

24.02 ± 2.10

12.21 ± 5.99

15.74 ± 5.35

19.97 ± 4.98

 Serum SV2A, mean (pg/mL) (SD)

5297.76 ± 3734.08

2367.11 ± 1601.60**

1327.56 ± 1290.37**

4497.22 ± 3059.41††

3974.93 ± 2952.57††

 Serum NfL, mean (pg/mL) (SD)

13.77 ± 9.89

16.30 ± 9.91*

20.33 ± 14.78**

38.54 ± 39.64**††

12.22 ± 6.73††

 Serum GFAP, mean (pg/mL) (SD)

8.28 ± 7.55

15.22 ± 8.45**

20.78 ± 10.54**

15.12 ± 10.27**††

12.99 ± 8.48**††

 Serum p-tau217, mean (pg/mL) (SD)

1.68 ± 1.37

3.67 ± 1.69**

4.38 ± 2.50**

3.53 ± 3.04**†

4.44 ± 2.60**

CSF

     

 No.

35

14

46

13

13

 Sex, female/male

18/17

8/6

31/15

5/8

4/9

 Age, years (SD)

62.23 ± 8.43

64.86 ± 8.52

61.80 ± 7.37

67 ± 10.81

64.92 ± 8.80

 Education level, years (SD)

NA

12.79 ± 2.21

10.22 ± 4.35

10.08 ± 4.34

11.92 ± 3.83

 MMSE score, mean (SD)

NA

27.96 ± 1.04

17.14 ± 6.34

20.42 ± 5.04

23.20 ± 2.76

 MOCA score, mean (SD)

NA

24.02 ± 2.10

12.21 ± 5.99

15.74 ± 5.35

19.97 ± 4.98

 CSF SV2A, mean (pg/mL) (SD)

7223.10 ± 2150.76

5279.63 ± 876.46**

3109.15 ± 1819.14**

6288.36 ± 1818.16††

6395.49 ± 1472.95††

  1. Note: The normality of the distribution of the variables was assessed by the Shapiro–Wilk test. Continuous variables were compared between two independent samples using the t-test or the Mann–Whitney U test. Chi-square test was used to assess sex. Logistic regression models were employed to compare continuous variables between different groups before and after adjusting for covariates such as age and sex. *p < 0.05 and **p < 0.01, compared with control; †p < 0.05 and ††p < 0.01, compared with AD.
  2. Abbreviations: AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; Con, control subjects; GFAP, glial fibrillary acidic protein; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; NA, not available; NfL, neurofilament light; p-tau217, phosphorylated tau; PDD, Parkinson’s disease dementia; SD, standard deviation; VaD, vascular dementia. SV2A, synaptic vesicle glycoprotein 2 A
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193